{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:20:48Z","timestamp":1788470448949,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jfma.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:53:49Z","timestamp":1684425229000},"page":"1101-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Gene therapy for hemophilia, a clinical viewpoint"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-019X","authenticated-orcid":false,"given":"Sheng-Chieh","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-5581","authenticated-orcid":false,"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jfma.2021.07.017","article-title":"Evolution of congenital haemophilia care in Taiwan","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"5235","key":"10.1016\/j.jfma.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"5644","key":"10.1016\/j.jfma.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.jfma.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2011.04369.x","article-title":"Gene therapy for haemophilia: a long and winding road","volume":"9","author":"High","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.jfma.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jfma.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jfma.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.jfma.2023.05.008_bib12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jfma.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jfma.2023.05.008_bib14","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-9822(02)00482-7","article-title":"Codon usage limitation in the expression of HIV-1 envelope glycoprotein","volume":"6","author":"Haas","year":"1996","journal-title":"Curr Biol"},{"issue":"8","key":"10.1016\/j.jfma.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jfma.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.05.008_bib19","article-title":"Updated results of the alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","author":"Nathan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2023.05.008_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-Human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years","author":"Pipe","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jfma.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.05.008_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year","author":"George","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2023.05.008_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia a using a novel human factor VIII variant","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2023.05.008_bib25","series-title":"Results from a phase 1\/2 safety and dose escalation study of TAK-754, an AAV8 vector with a codon-optimized B-domain-deleted factor VIII transgene in severe hemophilia A","first-page":"122","author":"Chapin","year":"2021"},{"issue":"12","key":"10.1016\/j.jfma.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood.V84.12.4214.bloodjournal84124214","article-title":"Role of the B domain for factor VIII and factor V expression and function","volume":"84","author":"Pittman","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jfma.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib28","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jfma.2023.05.008_bib29","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.jfma.2023.05.008_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"issue":"23","key":"10.1016\/j.jfma.2023.05.008_bib32","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jfma.2023.05.008_bib33","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jfma.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1074\/jbc.273.20.12089","article-title":"Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity","volume":"273","author":"Chang","year":"1998","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.jfma.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jfma.2023.05.008_bib36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1160\/TH13-02-0154","article-title":"Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jfma.2023.05.008_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1160\/TH09-11-0792","article-title":"FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis","volume":"104","author":"Kao","year":"2010","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.jfma.2023.05.008_bib38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1538-7836.2010.03913.x","article-title":"Generation of a novel factor IX with augmented clotting activities in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Lin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jfma.2023.05.008_bib39","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"Robinson","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.jfma.2023.05.008_bib40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMe2212347","article-title":"Hemophilia A gene therapy - some answers, more questions","volume":"388","author":"George","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.05.008_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of more than 5 Years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2023.05.008_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2021000254","article-title":"Hemophilia gene therapy: ushering in a new treatment paradigm?","volume":"2021","author":"George","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.jfma.2023.05.008_bib43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2023.05.008_bib44","article-title":"Etranacogene dezaparvovec for hemophilia B gene therapy","volume":"2","author":"Thornburg","year":"2021","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"10.1016\/j.jfma.2023.05.008_bib45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jfma.2023.05.008_bib46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jfma.2023.05.008_bib47","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2009.150","article-title":"Strategies to modulate immune responses: a new frontier for gene therapy","volume":"17","author":"Arruda","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jfma.2023.05.008_bib48","doi-asserted-by":"crossref","first-page":"658038","DOI":"10.3389\/fimmu.2021.658038","article-title":"Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies","volume":"12","author":"Chu","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jfma.2023.05.008_bib49","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.jfma.2023.05.008_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"issue":"17","key":"10.1016\/j.jfma.2023.05.008_bib51","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.jfma.2023.05.008_bib52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jfma.2023.05.008_bib53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib54","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jfma.2023.05.008_bib55","author":"Pipe","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2023.05.008_bib56","article-title":"Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B","author":"Schmidt","year":"2021","journal-title":"Res Pract Thrombosis Haemost"},{"key":"10.1016\/j.jfma.2023.05.008_bib57","article-title":"Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A","author":"Laffan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jfma.2023.05.008_bib58","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jfma.2023.05.008_bib59","doi-asserted-by":"crossref","first-page":"857276","DOI":"10.3389\/fimmu.2022.857276","article-title":"Overcoming the challenges imposed by humoral immunity to AAV vectors to achieve safe and efficient gene transfer in seropositive patients","volume":"13","author":"Gross","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jfma.2023.05.008_bib60","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jfma.2023.05.008_bib61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/mthe.2000.0042","article-title":"Stable transduction of actively dividing cells via a novel adenoviral\/episomal vector","volume":"1","author":"Leblois","year":"2000","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/hae.12608","article-title":"Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres","volume":"21","author":"Nakar","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib63","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib64","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib65","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jfma.2023.05.008_bib66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jfma.2023.05.008_bib67","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.05.008_bib68","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jfma.2023.05.008_bib69","article-title":"Current and future therapies for haemophilia-Beyond factor replacement therapies","author":"Nogami","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jfma.2023.05.008_bib70","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2023.05.008_bib71","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex\u00a0vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.jfma.2023.05.008_bib72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.jfma.2023.05.008_bib73","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jfma.2023.05.008_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12576","article-title":"Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety","volume":"5","author":"Mahlangu","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jfma.2023.05.008_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \u201chemophilia-free mind\u201d \u2013 the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:49:55Z","timestamp":1760539795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0929664623001596"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.05.008","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for hemophilia, a clinical viewpoint","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}